截至发稿，昭衍新药(06127.HK)涨9.72%、泰格医药(03347.HK)涨5.94%、康龙化成(03759.HK)涨 3.68%。 本文源自：金融界AI电报 ...

Company Dynamics - Zhou Zhiwen, a major shareholder and actual controller of Zhaoyan New Drug (603127.SH), has announced a significant share reduction plan, potentially cashing out over 500 million yuan based on the current stock price [2] - Before the reduction, Zhou held 74,725,981 shares, accounting for 9.9704% of the total share capital, with a combined holding of 32.274% with his spouse, Feng Yuxia [2] - Following the announcement of the share reduction, Zhaoyan New Drug's stock dropped by 6.20% on December 30, closing at 34.80 yuan, indicating a potential cash-out of over 500 million yuan from the sale of 14.98 million shares [2] Industry Insights - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, gaining prominence in the capital market due to its assets in experimental monkeys [2] - The average market price of experimental monkeys has seen significant fluctuations, with prices rising from 13,800 yuan per monkey in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] - In November 2023, the price of experimental monkeys dropped to approximately 113,000 yuan each, reflecting a decrease of over 30% from the peak [3] - Despite a decline in revenue by 26.23% year-on-year to 985 million yuan in the first three quarters of 2025, Zhaoyan New Drug managed to achieve a net profit of 80.71 million yuan, indicating a recovery in performance [3] - As of December 29, 2025, Zhaoyan New Drug's stock price has increased by over 120% within the year [3] Shareholder Activity - Zhou Zhiwen has a history of share reductions, having sold a total of 14.11 million shares since November 2020, resulting in approximately 915 million yuan in cash [4]

Core Viewpoint - The stock price of Zhaoyan New Drug (603127.SH) surged due to the rebound in the market price of experimental monkeys, prompting major shareholder Zhou Zhiwen to announce a significant share reduction plan, potentially cashing out over 500 million yuan [1] Group 1: Shareholder Actions - Zhou Zhiwen plans to reduce his holdings by up to 14,980,000 shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital, within three months after the announcement [1] - Prior to the reduction, Zhou Zhiwen held 74,725,981 shares, accounting for 9.9704% of the company, with the couple's total holding at 32.274% [1] - Following the announcement of the share reduction, Zhaoyan New Drug's stock fell by 6.20% to a closing price of 34.80 yuan [1] Group 2: Company Overview - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, with a notable focus on experimental monkeys, which are critical for various research fields [2] - The price of experimental monkeys has fluctuated significantly, with the average market price rising from 13,800 yuan in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] Group 3: Financial Performance - In Q1 2024, Zhaoyan New Drug reported a revenue of 325 million yuan, a year-on-year decrease of 12.07%, and a net loss of 272 million yuan, attributed to a 284 million yuan loss from changes in the fair value of biological assets [3] - By the first three quarters of 2025, the company achieved a revenue of 985 million yuan, a year-on-year decrease of 26.23%, but turned a profit with a net income of 80.71 million yuan [3] - The stock price of Zhaoyan New Drug increased by over 120% throughout the year, reflecting a recovery in the market price of experimental monkeys [3] Group 4: Market Perception - Some market analysts argue that Zhaoyan New Drug primarily sells experimental services rather than monkeys, suggesting that monkey prices do not directly reflect the company's sustainable profitability [4] - Despite this, fluctuations in the value of experimental monkeys significantly impact the company's financial performance, leading to potential distortions in financial reporting [4]

证券之星消息，12月30日医疗服务板块较上一交易日下跌0.73%，昭衍新药领跌。当日上证指数报收于 3965.12，下跌0.0%。深证成指报收于13604.07，上涨0.49%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920670 | 数字人 | 15.87 | 4.20% | 5.91万 | 9396.08万 | | 600568 | ST中珠 | 2.52 | 2.86% | 22.48万 | 5686.21万 | | 300347 | 泰格医药 | 56.63 | 1.27% | 9.14万 | 5.16亿 | | 688621 | 阳光诺和 | 64.18 | 1.20% | 1.74万 | 1.10亿 | | 688131 | 皓元医药 | 72.54 | 0.96% | 2.24万 | 1.62亿 | | 301096 | 百诚医药 | 57.75 | 0.70% | 3.10万 | 1.78亿 | | 300363 | 博腾股份 | 23.45 ...

中国经济网北京12月30日讯 昭衍新药（603127）(603127.SH)昨晚发布关于股东减持股份计划公告。 截至公告披露日，公司实际控制人之一周志文持有公司股票74,725,981股，占公司总股本9.9704%，其持有的股份来 源于首发前限售股份及公司资本公积金转增股份等。 周志文拟自减持计划公告之日起15个交易日后的3个月内通过上海证券交易所以集中竞价或大宗交易的方式减持不超 过14,980,000股,不超过其持有股份的20.0466%，不超过公司总股本的1.99873%。减持计划实施期间，公司若发生送 红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应调整。减持价格依据市场价格确定。 按照12月29日收盘价37.1元测算，周志文套现金额约合5.56亿元。 昭衍新药2024年年度报告显示，公司实际控制人是冯宇霞（女）、周志文（男）夫妇。 昭衍新药表示，本次减持计划是股东根据自身资金需要进行的减持，本次减持不会对公司治理结构及持续经营情况 产生重大影响。在减持期间内，股东将根据市场情况、公司股价及有关规则所允许的可交易窗口期间等因素选择是 否实施本计划，因此减持时间、减持价格、减持数量存在 ...

每经AI快讯，昭衍新药(06127.HK)跌超6%，截至发稿跌6.25%，报19.8港元，成交额8459.44万港元。 （文章来源：每日经济新闻） ...

智通财经APP获悉，昭衍新药(06127)跌超6%，截至发稿，跌6.25%，报19.8港元，成交额8459.44万港 元。 消息面上，12月29日，昭衍新药发公告称，公司实际控制人之一周志文拟自减持计划公告之日起15个交 易日后的3个月内通过集中竞价或大宗交易的方式减持不超过1498万股，不超过其持有股份的 20.0466%，不超过公司总股本的1.99873%。截至该公告披露日，周志文持有昭衍新药股票7472.6万股， 占公司总股本的9.9704%，股份来源于IPO前取得及公司资本公积金转增，减持原因为自身资金需求。 ...

昭衍新药（603127）(06127)跌超6%，截至发稿，跌6.25%，报19.8港元，成交额8459.44万港元。 消息面上，12月29日，昭衍新药发公告称，公司实际控制人之一周志文拟自减持计划公告之日起15个交 易日后的3个月内通过集中竞价或大宗交易的方式减持不超过1498万股，不超过其持有股份的 20.0466%，不超过公司总股本的1.99873%。截至该公告披露日，周志文持有昭衍新药股票7472.6万股， 占公司总股本的9.9704%，股份来源于IPO前取得及公司资本公积金转增，减持原因为自身资金需求。 ...

Summary of the Conference Call for Zhaoyan New Drug Industry Overview - The conference call focuses on the safety evaluation (安评) industry, particularly the supply and demand dynamics of experimental monkeys, which are crucial for drug development and testing [2][5]. Key Points and Arguments 1. **Strategic Advantage in Monkey Supply**: Zhaoyan possesses its own monkey breeding facilities, which provides a strategic advantage in a market where the supply of experimental monkeys, especially F2 generation monkeys, is limited due to long breeding cycles [2][4]. 2. **Profit Growth and Valuation Potential**: The company has achieved growth in net profit attributable to shareholders through the appreciation of biological assets and increased service fees, indicating significant potential for valuation enhancement as it transitions from preclinical to clinical stages [2][4]. 3. **Industry Leadership**: With 30 years of experience in the safety evaluation industry, Zhaoyan is one of the leading companies in China, holding GLP qualifications from multiple regulatory bodies including NMPA, FDA, and OECD, which allows it to meet global IND approval requirements [2][4]. 4. **High Barriers to Entry**: The safety evaluation industry has high entry barriers due to the substantial costs and long timelines associated with GLP laboratory construction, resulting in a high outsourcing rate. Zhaoyan's qualifications and experience position it favorably in the competitive landscape [2][5]. 5. **Offshore Outsourcing Growth**: The company has leveraged domestic monkey resources and labor to secure high-value offshore orders, achieving a 60% year-on-year growth in offshore outsourcing orders, which is expected to further expand its market share [2][5]. 6. **Supply and Demand Imbalance**: The industry currently faces a mismatch between supply and demand, with a decline in the supply of experimental monkeys due to price differences between China and the U.S., as well as a decrease in birth rates caused by aging populations [6]. 7. **Rising Prices and Service Fees**: The supply-demand imbalance has led to an increase in the price of experimental monkeys, currently exceeding 100,000 yuan per monkey, alongside rising service fees, contributing to an upward trend in the industry's overall prosperity [6]. Future Development Trends 1. **Increased Investment in Innovative Drug Development**: There is a growing investment in innovative drug development driven by factors such as active IPOs in Hong Kong and increased fundraising activities, which is expected to significantly boost demand for safety evaluation services [3][7]. 2. **Continued Tightness in Monkey Resources**: The ongoing tightness in experimental monkey resources is anticipated to persist due to long breeding cycles and low output rates, enhancing Zhaoyan's bargaining power and ability to command premium service fees [3][7]. 3. **Expansion of Offshore Outsourcing Market**: As global resources for experimental monkeys become scarcer, Zhaoyan is well-positioned to further penetrate the offshore outsourcing market, potentially securing higher-margin orders and driving business growth [3][7].

昭衍新药（603127）(603127.SH)公告，公司实际控制人之一周志文拟自减持计划公告之日起15个交易 日后的3个月内通过集中竞价或大宗交易的方式减持不超过1498万股，不超过其持有股份的20.0466%， 不超过公司总股本的1.99873%。 ...